Cardiovascular risk factors in Systemic Lupus Erythematosus and in antiphospholipid syndrome;Fattori di rischio cardiovascolare nel lupus eritematoso sistemico e nella sindrome da anticorpi antifosfolipidi

Minerva Medica

Volumn 94, Issue 2, 2003, Pages 63-70

  Sarzi Puttini, P ^a   Atzeni, F ^a   Carrabba, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Antiphospholipid syndrome; Risk factors; Systemic Lupus Erythematosus

Indexed keywords

APOLIPOPROTEIN A1; CARDIOLIPIN ANTIBODY; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPID; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; HOSPITALIZATION; HUMAN; REVIEW; RISK ASSESSMENT; RISK FACTOR; SURVIVAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIPHOSPHOLIPID SYNDROME; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYPERHOMOCYSTEINEMIA; LUPUS ERYTHEMATOSUS, SYSTEMIC; RISK FACTORS;

EID: 0041345728     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Li EK. Systemic lupus erythematosus. In: Sung JY, Li PK, Sanderson JE, Woo J, editors. Textbook of clinical medicine for Asia. Hong Kong: Chinese University Press; 1988.p.569-79.
2. Merrell M, Shulman LE. Determination of prognosis in chronic disease illustrated by systemic lupus erythematosus. J Chronic Dis 1955;1:12-32.
3. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT. Mortality studies in systemic lupus erythematosus. Results from a single centre. III. Improved survival over 24 years. J Rheumatol 1997;24:1061-5.
4. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976;60:221-5.
5. Aranow C, Ginzler EM. Epidemiology of cardiovascular disease in systemic lupus erythematosus. Lupus 2000;9:166-9.
6. Petri M, Perez-Gutthann SS, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992;93:513-9.
7. Gladman DD, Urowitz MB. Morbidity in systemic lupus erythematosus. J Rheumatol 1987;14:223-6.
8. Hosenpud JD, Montanaro A, Hart MV, Haines JE, Specht HD, Bennett RM et al. Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus. Am J Med 1984;77:286-92.
9. Kiat M, Bermands DS, Maddami J. Myocardial perfusion imaging using technetium-99 m radiopharmaceuticals. Radiol Clin North Am 1993;31:795-815.
10. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
11. Alder S, Cohen AH, Glassock RJ. Secondary glomerular diseases. In: Brenner BM, editor. The kidney. Philadelphia: Saunders; 1996.p.1498.
12. Balow JE. Kidney disease in systemic lupus erythematosus. Rheumatol Int 1991;11:113-5.
13. Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:257-78.
14. Petri M, Spence D, Bone LR, Hochberg MC. Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. Medicine 1992;71:291-302.
15. Ilowite NT, Samuel P, Ginzler E, Jacobson MS. Dyslipoproteinemia in pedriatric systemic lupus erythematosus. Arthritis Rheum 1988;31:859-63.
16. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity and anticardiolipin antibodies. Lupus 1997;6:533-9.
17. Borba EF, Bonfa E, Vinagre CG, Ramires JA, Maranhao RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000;43:1033-40.
18. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein Al in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1566-74.
19. Dinu AR, Merrill JT, Sutton-Tyrrell K. Autoantibodies to apoliprotein A1 (APOA1) in an SLE population: relationship to HDL levels and to carotid atherosclerosis by ultrasound assessment. Arthritis Rheum 1988;41:S139.
20. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990;301:1248-51.
21. Petri M, Miller J, Ebert RF, Goldman D. Lipoprotein a (Lp[a]) is predictive of myocardial infarction in SLE. Arthritis Rheum 1995,38:S404.
22. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B et al. Hyperhomocysteinemia: an indipendent risk factor for vascular disease. N Engl J Med 1991;324:1149-55.
23. D'Angelo SV, Mazzola G, Crippa L, Fermo I, Vigano D'Angelo S. Hyperhomocysteinemia and venosus thromboembolic disease. Haematologia 1997;82:211-9.
24. Guba SC, Fink LM, Fonseca V. Hyperhomocysteinemia. An emerging and important risk factor for thromboembolic and cardiovascular disease. Am J Clin Pathol 1996;106:709-22.
25. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteiemia in an elderly population. JAMA 1993;270:2693-8.
26. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 1996;348:1120-4.
27. Fijnheer R, Roest M, Haas FJ, De Groot PG, Derksen RH. Homocysteine, methylene-tetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in SLE: a retrospective cohort study. J Rheumatol 1998;25:1737-42.
28. Minick CR, Murphy GE, Campbell WGI. Experimental induction of athero-arteriosclerosis by sinergy of allergic injury to arteries and lipid-rich diet. Effect of repeated injection of horse serum in rabbits fed a dietary cholesterol supplement. J Exp Med 1966;124:635-52.
29. Kabakow AE, Tertow VV, Saenko VA, Poverenny AM, Orekhov AN. The atherogenic effect of lupus sera: systemic lupus erythemosus-derived immune complxes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin Immunol Immunopathol 1992;63:214-20.
30. Reiss AB, Malhotra S, Javitt NB, Grossi EA, Galloway AC, Montesinos MC et al. Occupancy of Clq receptors on endothelial cells by immune complexes downregulates mRNA for sterol 27-idroxilase the major mediator of extra-hepatic cholesterol metabolism. Arthritis Rheum 1998;41:S79.
31. Malle E, De Beer FC. Human serum amyloid A (SSA): a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996;26:427-35.
32. Pruzanski W, De Beer FC, De Beer MC, Stefanski E, Vadas P. Serum amyloid A protein enhances the activity of secretory pancreatic phospholipase A2. Biochem J 1995;309:461-4.
33. Pruzanski W, Goulding NJ, Flower RJ, Gladman DD, Urowitz MB, Goodman PJ et al. Circulating group II phospholipasi A2 activity and antilipocortin antibodies in SLE. Correlative study with disease activity. J Rheumatol 1994;21:252-7.
34. Ettinger WH, Goldeberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987;83:503-8.
35. MacGregor AJ, Dhillon VB, Binder A, Forte CA, Knight BC, Betteridge DJ et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Am Rheum Dis 1992;51:152-5.
36. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994;21:1264-7.
37. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med 1994;96:254-9.
38. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxichloroquine in patients with rheumatic disease: reversal of deleterious effects of steroid on lipids. Am J Med 1990;89:322-6.
39. Rahman P, Gladman DD, Urowitz MB, Yuen K, Hallett D, Bruce IN. The cholesterol lowering effect of antimalarial drugs in enhanced in lupus patients on corticosteroid drugs. J Rheumatol 1999;26:325-30.
40. Urowitz MB, Gladman DD, Bruce IN. Atherosclerosis and systemic lupus erythematosus. Current Rheumatol Reports 2000;2:19-23.
41. Hodis HN, Quismorio FP Jr, Wickham E, Blankenhorm DH. The lipid, lipoprotein and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993;20:661-5.
42. Tam LS, Gladman DD, Hallett DC, Rahman P, Urowitz MB. Effect of antimalarial agents on fasting lipid profile in SLE. J Rheumatol 2000;27:2142-5.
43. Asherson RA, Cervera R, Piette JC. The antiphospholipid sindrome. Boca Raton: CRP Press; 1996.
44. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol 1985;3:285-6.
45. Turiel M, Sarzi-Puttini P, Atzeni F, Muzzupuppa S, Rossi E, Parsons W. Thrombotic risk factors in primary antiphospholipid syndrome: a 5-year prospective study. Submitted for publication.
46. Urowitz MB, Gladman DD. Accelerated atheroma in Lupus-background. Lupus 2000;9:161-5.
47. Lin YL, Wang CT. Activaction of human platelets by rabbit anticardiolipin antibodies. Blood 1992;80:3135-43.
48. Sheren Y, Black M, Vaarala O. Anti-prothrombin antibodies in thrombosis and atherosclerosis. In: Atherosclerosis and Autoimmunity. In: Shoenfeld Y, Harats D, Wick G, editors. Amsterdam: Elsevier; 2001.p.185-190.
49. Cariou R, Tobelem G, Bellucci S. Effect of lupus anticoagulant on antithrombotic properties of endothelial cells-inibition of thrombomodulin-dependent protein C activation. Tromb Haemost 1988;60:54-8.
50. Silver RK, Adler L, Hickman AR, Hageman JR. Anticardiolipin antibody-positive serum enhances endothelial cell platelet-activating factor production. Am J Obstet Gynecol 1991;165:1748-52.
51. George J, Afek A, Gilburd B, Harats D, Shoenfeld Y. Autoimmunity in atherosclerosis: lessons from experimental models. Lupus 2000;3:223-7.
52. George J, Afek A, Gilburd B, Blank M, Levy Y, Aron-Maor A et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with β2-glycoprotein I. Circulation 1998;98:1108-15.
53. Hasunuma Y, Matsuura E, Makita Z, Katahira T, Nishi S, Koike T. Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997;107:569-73.
54. Sherer Y, Shoenfeld Y. Antiphospholipid syndrome, Antiphospholipid antibodies, and atherosclerosis. Current Atheroscl Reports 2001;3:328-33.
55. Klemp P, Cooper RC, Strauss FJ, Jordaan ER, Przybojewsky JZ, Nel N. Anti-cardiolipin antibodies in ischaemic heart disease. Clin Exp Immunol 1988;74:254-7.
56. Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K et al. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulatiom 1995;91:23-7.
57. Wu R, Nityanand S, Berglund L, Lithell H, Holm G, Lefvert AK. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997;17:3159-63.
58. Farsi A, Domeneghetti MP, Fedi S, Capanni M, Giusti B, Marcucci R et al. High prevalence of anti-β2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity 1999;30:93-8.